Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.

DART Trial Team., Mugyenyi P, Walker AS, Hakim J, Munderi P, Gibb DM, Kityo C, Reid A, Grosskurth H, Darbyshire JH, Ssali F, Bray D, Katabira E, Babiker AG, Gilks CF, Grosskurth H, Munderi P, Kabuye G, Nsibambi D, Kasirye R, Zalwango E, Nakazibwe M, Kikaire B, Nassuna G, Massa R, Fadhiru K, Namyalo M, Zalwango A, Generous L, Khauka P, Rutikarayo N, Nakahima W, Mugisha A, Todd J, Levin J, Muyingo S, Ruberantwari A, Kaleebu P, Yirrell D, Ndembi N, Lyagoba F, Hughes P, Aber M, Lara AM, Foster S, Amurwon J, Wakholi BN, Whitworth J, Wangati K, Amuron B, Kajungu D, Nakiyingi J, Omony W, Fadhiru K, Nsibambi D, Khauka P, Mugyenyi P, Kityo C, Ssali F, Tumukunde D, Otim T, Kabanda J, Musana H, Akao J, Kyomugisha H, Byamukama A, Sabiiti J, Komugyena J, Wavamunno P, Mukiibi S, Drasiku A, Byaruhanga R, Labeja O, Katundu P, Tugume S, Awio P, Namazzi A, Bakeinyaga GT, Katabira H, Abaine D, Tukamushaba J, Anywar W, Ojiambo W, Angweng E, Murungi S, Haguma W, Atwiine S, Kigozi J, Namale L, Mukose A, Mulindwa G, Atwiine D, Muhwezi A, Nimwesiga E, Barungi G, Takubwa J, Murungi S, Mwebesa D, Kagina G, Mulindwa M, Ahimbisibwe F, Mwesigwa P, Akuma S, Zawedde C, Nyiraguhirwa D, Tumusiime C, Bagaya L, Namara W, Kigozi J, Karungi J, Kankunda R, Enzama R, Latif A, Hakim J, Robertson V, Reid A, Chidziva E, Bulaya-Tembo R, Musoro G, Taziwa F, Chimbetete C, Chakonza L, Mawora A, Muvirimi C, Tinago G, Svovanapasis P, Simango M, Chirema O, Machingura J, Mutsai S, Phiri M, Bafana T, Chirara M, Muchabaiwa L, Muzambi M, Mutowo J, Chivhunga T, Chigwedere E, Pascoe M, Warambwa C, Zengeza E, Mapinge F, Makota S, Jamu A, Ngorima N, Chirairo H, Chitsungo S, Chimanzi J, Maweni C, Warara R, Matongo M, Mudzingwa S, Jangano M, Moyo K, Vere L, Mdege N, Machingura I, Katabira E, Ronald A, Kambungu A, Lutwama F, Mambule I, Nanfuka A, Walusimbi J, Nabankema E, Nalumenya R, Namuli T, Kulume R, Namata I, Nyachwo L, Florence A, Kusiima A, Lubwama E, Nairuba R, Oketta F, Buluma E, Waita R, Ojiambo H, Sadik F, Wanyama J, Nabongo P, Oyugi J, Sematala F, Muganzi A, Twijukye C, Byakwaga H, Ochai R, Muhweezi D, Coutinho A, Etukoit B, Gilks C, Boocock K, Puddephatt C, Grundy C, Bohannon J, Winogron D, Gibb DM, Burke A, Bray D, Babiker A, Walker AS, Wilkes H, Rauchenberger M, Sheehan S, Spencer-Drake C, Taylor K, Spyer M, Ferrier A, Naidoo B, Dunn D, Goodall R, Darbyshire JH, Peto L, Nanfuka R, Mufuka-Kapuya C, Kaleebu P, Pillay D, Robertson V, Yirrell D, Tugume S, Chirara M, Katundu P, Ndembi N, Lyagoba F, Dunn D, Goodall R, McCormick A, Lara AM, Foster S, Amurwon J, Wakholi BN, Kigozi J, Muchabaiwa L, Muzambi M, Weller I, Babiker A, Bahendeka S, Bassett M, Wapakhabulo AC, Darbyshire JH, Gazzard B, Gilks C, Grosskurth H, Hakim J, Latif A, Mapuchere C, Mugurungi O, Mugyenyi P, Burke C, Jones S, Newland C, Pearce G, Rahim S, Rooney J, Smith M, Snowden W, Steens JM, Breckenridge A, McLaren A, Hill C, Matenga J, Pozniak A, Serwadda D, Peto T, Palfreeman A, Borok M, Katabira E.

Lancet. 2010 Jan 9;375(9709):123-31. doi: 10.1016/S0140-6736(09)62067-5. Epub 2009 Dec 8.

2.

Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals.

Ouyang DW, Brogly SB, Lu M, Shapiro DE, Hershow RC, French AL, Leighty RM, Thompson B, Tuomala RE.

AIDS. 2010 Jan 2;24(1):109-14. doi: 10.1097/QAD.0b013e3283323941.

3.

Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure.

Ouyang DW, Shapiro DE, Lu M, Brogly SB, French AL, Leighty RM, Thompson B, Tuomala RE, Hershow RC.

AIDS. 2009 Nov 27;23(18):2425-30. doi: 10.1097/QAD.0b013e32832e34b1.

4.

Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals.

Vogel M, Bertram N, Wasmuth JC, Wyen C, Voigt E, Schwarze-Zander C, Sudhop T, Fätkenheuer G, Rockstroh JK, Reichel C.

J Antimicrob Chemother. 2009 May;63(5):988-91. doi: 10.1093/jac/dkp044. Epub 2009 Mar 6.

PMID:
19270314
5.

Does gender and nevirapine (NVP) influence abnormal liver functions in HIV disease?

Sundaram M, Srinivas CN, Solomon S, Shankar EM, Balakrishnan P, Kumarasamy N.

J Infect. 2009 Mar;58(3):255-7. doi: 10.1016/j.jinf.2009.01.003. Epub 2009 Feb 7. No abstract available.

PMID:
19201032
6.

Risk for immune-mediated liver reactions by nevirapine revisited.

Medrano J, Barreiro P, Tuma P, Vispo E, Labarga P, Blanco F, Soriano V.

AIDS Rev. 2008 Apr-Jun;10(2):110-5. Review.

PMID:
18615121
7.

Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts.

De Lazzari E, León A, Arnaiz JA, Martinez E, Knobel H, Negredo E, Clotet B, Montaner J, Storfer S, Asenjo MA, Mallolas J, Miró JM, Gatell JM.

HIV Med. 2008 Apr;9(4):221-6. doi: 10.1111/j.1468-1293.2008.00552.x.

8.

Variation of CD4 count and percentage during pregnancy and after delivery: implications for HAART initiation in resource-limited settings.

Ekouevi DK, Inwoley A, Tonwe-Gold B, Danel C, Becquet R, Viho I, Rouet F, Dabis F, Anglaret X, Leroy V.

AIDS Res Hum Retroviruses. 2007 Dec;23(12):1469-74.

PMID:
18160003
9.

Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens.

Jamisse L, Balkus J, Hitti J, Gloyd S, Manuel R, Osman N, Djedje M, Farquhar C.

J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):371-6.

PMID:
17259905
10.

Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.

Rivero A, Mira JA, Pineda JA.

J Antimicrob Chemother. 2007 Mar;59(3):342-6. Epub 2007 Jan 25. Review.

PMID:
17255142
11.

Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy.

Lyons F, Hopkins S, Kelleher B, McGeary A, Sheehan G, Geoghegan J, Bergin C, Mulcahy FM, McCormick PA.

HIV Med. 2006 May;7(4):255-60.

12.

Nevirapine toxicity in a cohort of HIV-1-infected pregnant women.

João EC, Calvet GA, Menezes JA, D'Ippolito MM, Cruz ML, Salgado LA, Matos HJ.

Am J Obstet Gynecol. 2006 Jan;194(1):199-202.

PMID:
16389032
13.

Hepatotoxicity of antiretrovirals: incidence, mechanisms and management.

Núñez M.

J Hepatol. 2006;44(1 Suppl):S132-9. Epub 2005 Nov 28. Review.

PMID:
16364487
14.

Are adverse events of nevirapine and efavirenz related to plasma concentrations?

Kappelhoff BS, van Leth F, Robinson PA, MacGregor TR, Baraldi E, Montella F, Uip DE, Thompson MA, Russell DB, Lange JM, Beijnen JH, Huitema AD; 2NN Study Group..

Antivir Ther. 2005;10(4):489-98.

PMID:
16038474
15.

The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.

van Leth F, Andrews S, Grinsztejn B, Wilkins E, Lazanas MK, Lange JM, Montaner J; 2NN study group..

AIDS. 2005 Mar 25;19(5):463-71.

PMID:
15764851
16.

Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022.

Hitti J, Frenkel LM, Stek AM, Nachman SA, Baker D, Gonzalez-Garcia A, Provisor A, Thorpe EM, Paul ME, Foca M, Gandia J, Huang S, Wei LJ, Stevens LM, Watts DH, McNamara J; PACTG 1022 Study Team..

J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):772-6.

PMID:
15213559
17.

Hepatotoxicity associated with nevirapine use.

Baylor MS, Johann-Liang R.

J Acquir Immune Defic Syndr. 2004 Apr 15;35(5):538-9. Review. No abstract available.

PMID:
15021321
18.

Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors.

Dieterich DT, Robinson PA, Love J, Stern JO.

Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S80-9.

PMID:
14986279
19.

Grade 4 events are as important as AIDS events in the era of HAART.

Reisler RB, Han C, Burman WJ, Tedaldi EM, Neaton JD.

J Acquir Immune Defic Syndr. 2003 Dec 1;34(4):379-86.

PMID:
14615655
20.

Efficacy and durability of nevirapine in antiretroviral-experienced patients.

Harris M.

J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S53-8. Review.

PMID:
14562858

Supplemental Content

Support Center